fluorouracil has been researched along with Carcinoma, Transitional Cell in 165 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Excerpt | Relevance | Reference |
---|---|---|
"We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 9.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
"The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer." | 7.65 | Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. ( Cross, RJ; Glashan, RW; Humphrey, CS; Robinson, RG; Smith, PH; Williams, RE, 1976) |
"Eligible patients had muscle invasive bladder cancer (clinical stages T2-T4) with nodal involvement at or below the level of bifurcation of the iliac vessels, were medically or surgically inoperable, or refused cystectomy." | 6.70 | Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001) |
"The nonrecurrence rate and side effects were both compared among the 4 groups." | 6.68 | Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Kuriya, N; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1997) |
"5-Fluorouracil was administered p." | 6.66 | Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987) |
"Twenty-three muscle-invasive bladder cancer patients who were unfit for or unwilling to receive radical cystectomy were enrolled in this study." | 5.32 | Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. ( Chang, PL; Chen, CS; Chen, MF; Chen, WC; Chu, SH; Chuang, CK; Hong, JH; Liaw, CC; Lin, PY; Wu, CT, 2003) |
"To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 5.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
"We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 5.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
"The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
"A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811." | 5.17 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013) |
"We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
"Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil." | 3.79 | Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013) |
"5-fluorouracil (5-FU) is an anticancer agent widely used against various tumors including bladder cancer." | 3.72 | [Orotate phosphoribosyl transferase in bladder cancer]. ( Furuse, H; Harada, M; Hirano, Y; Mugiya, S; Ozono, S; Suzuki, K; Ushiyama, T, 2004) |
" We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients." | 3.72 | FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004) |
" The present study also suggested that we might be able to exclude cases of bladder cancer in which 5-fluorouracil group medicines would be inappropriate candidates in treatment options by measuring both TP and DPD levels in the tumor." | 3.71 | Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer. ( Hariu, K; Iizumi, T; Sato, M; Sato, S; Shimizu, H; Tomomasa, H; Umeda, T, 2002) |
" DPD is also the principal enzyme involved in the degradation of 5-fluorouracil (5-FU), which is one of the anticancer chemotherapeutic agents currently used in the treatment of bladder cancer." | 3.71 | The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. ( Fukushima, M; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O; Wada, H; Yoshida, O, 2001) |
"Treatment of the T24 human bladder cancer cell line with anti-Fas mAb in combination with 5-fluorouracil, mitomycin C or methotrexate did not overcome resistance to these agents." | 3.70 | Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). ( Bonavida, B; Mizutani, Y; Yoshida, O, 1998) |
"Concurrent 2-drug chemoradiotherapy with cisplatin and 5-fluorouracil is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive bladder cancer." | 3.70 | [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study]. ( Berger, C; Chauvet, B; Davin, JL; Félix-Faure, C; Reboul, F; Vincent, P, 1998) |
"Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
"To improve the results obtained by cystectomy alone and to determine the possibilities of conservative treatment in invasive bladder cancer, we designed a prospective study using a combination of fluorouracil (5-FU) plus cisplatin and concomitant radiation therapy, followed by either cystectomy or additional chemoradiotherapy." | 3.68 | Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. ( Baillet, F; Brunel, P; Chretien, Y; Colardelle, F; Delanian, S; Dufour, B; Housset, M; Huart, J; Maulard, C, 1993) |
"Nineteen patients with locally advanced bladder cancer were treated with irradiation and concomitant 5-fluorouracil intravenous infusion with or without bolus mitomycin." | 3.67 | Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion. ( Aziz, H; Braverman, A; Choi, K; Laungani, GB; Macchia, R; Rosenthal, J; Rotman, M; Silverstein, M, 1987) |
"Two VPM-CisCF chemotherapy regimens (vincristine (VCR), peplomycin (PEP), methotrexate (MTX), cis-diamminedichloroplatinum (II) (CDDP), cytosine arabinoside (Ara-C) and 5-fluorouracil (5-FU), established using human bladder cancer xenografts in nude mice were applied for advanced urothelial cancer." | 3.67 | [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer]. ( Hida, S; Okada, K; Ooishi, K; Yamauchi, T; Yoshida, O, 1985) |
"Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
"Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)." | 3.66 | [Chemotherapy of metastatic urothelial carcinoma]. ( Kawai, T; Kihara, K; Ogawa, M; Sakuramoto, T; Washizuka, M, 1982) |
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
"Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate." | 3.65 | Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975) |
"The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer." | 3.65 | Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. ( Cross, RJ; Glashan, RW; Humphrey, CS; Robinson, RG; Smith, PH; Williams, RE, 1976) |
"18 patients with category T3 bladder cancer were treated with a combination of radical radiotherapy followed after an interval of 1-3 months by pulsed chemotherapy with adriamycin and 5-fluorouracil." | 3.65 | A toxicity study of the treatment of T3 bladder tumours with a combination of radiotherapy and chemotherapy. ( Glashan, RW; Houghton, AL; Robinson, MR, 1977) |
"Eligible patients had muscle invasive bladder cancer (clinical stages T2-T4) with nodal involvement at or below the level of bifurcation of the iliac vessels, were medically or surgically inoperable, or refused cystectomy." | 2.70 | Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001) |
"The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone." | 2.70 | A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001) |
" Dosage in subsequent cycles was adjusted according to toxicity." | 2.69 | A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. ( Kantoff, PW; Loughlin, KR; Manola, J; Oh, WK; Richie, JP, 1999) |
"Gallium nitrate and 5-FU were each administered by continuous 5-day infusions every 28 days." | 2.68 | Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. ( Bajorin, DF; Heineman, M; Hilton, S; Hirsch, J; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI, 1997) |
"The nonrecurrence rate and side effects were both compared among the 4 groups." | 2.68 | Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Kuriya, N; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1997) |
"or t." | 2.66 | [Phase II study of 5-FU tablet in bladder tumor]. ( Fukuoka, H; Fukushima, S; Furuhata, A; Ishizuka, E; Kondo, I; Kubota, Y; Moriyama, M; Nagamoto, A; Satomi, Y; Shuin, T, 1989) |
"5-Fluorouracil was administered p." | 2.66 | Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987) |
"The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg." | 2.65 | A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981) |
"Use of the conservative approach in bladder cancer now appears to be a tangible reality for selected patients, but these combined modalities have not yet been tested in randomized trials." | 2.40 | [Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?]. ( Baillet, F; Chrétien, Y; Dufour, B; Durdux, C; Housset, M; Méjean, A, 1998) |
"We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years." | 2.39 | Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995) |
"Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear." | 1.42 | Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients. ( Hayashi, N; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sakai, H; Sakamoto, I; Uetani, M, 2015) |
"Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs after intravesical live Bacillus Calmette-Guérin." | 1.38 | Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. ( Annels, NE; Coffin, RS; Harrington, KJ; Horvath, A; Melcher, AA; Metcalf, S; Mostafid, H; Pandha, HS; Pencavel, T; Peschard, P; Price, T; Seth, R; Simpson, GR, 2012) |
"At pretreatment assessment, anal cancer was identified by PET-CT in 47 patients (88." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
"Capecitabine was administered at a median dose of 1600 mg/m2/day (range, 1200-1800 mg/m2)." | 1.33 | A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. ( Fontana, J; Forman, J; Frazier, A; Patel, B; Pontes, E; Vaishampayan, U, 2005) |
"Twenty-three muscle-invasive bladder cancer patients who were unfit for or unwilling to receive radical cystectomy were enrolled in this study." | 1.32 | Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. ( Chang, PL; Chen, CS; Chen, MF; Chen, WC; Chu, SH; Chuang, CK; Hong, JH; Liaw, CC; Lin, PY; Wu, CT, 2003) |
"Of 149 consecutive patients treated for cancer of the bladder, 14 patients met eligibility criteria." | 1.32 | Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. ( Goffin, JR; Rajan, R; Souhami, L, 2004) |
"Superficial bladder cancer patients who had undergone transurethral resection were divided into two groups, a recurrent and a nonrecurrent group." | 1.32 | Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. ( Fujita, K; Hirano, Y; Kageyama, S; Suzuki, K; Ushiyama, T, 2003) |
" This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues." | 1.31 | Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001) |
"Animals bearing established B16 melanoma or MB-49 bladder carcinoma were used to study the most effective scheduling of recombinant murine IL-12 (rmIL-12), along with systemic chemotherapy." | 1.30 | Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. ( Ara, G; Buxton, D; Leonard, J; Schaub, RG; Teicher, BA, 1997) |
"Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy." | 1.30 | [Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998) |
"Treatment of bladder cancer by TURB and RT/RCT is an alternative to primary cystectomy." | 1.30 | Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. ( Birkenhake, S; Kühn, R; Martus, P; Sauer, R; Schrott, KM, 1998) |
"A human bladder cancer cell line resistant to adriamycin (ADM), T24/ADM9 has been established in vitro by exposing T24 parent cells to progressively higher concentrations of the drug over a period of 12 months." | 1.29 | Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. ( Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A, 1995) |
"To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 1.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
"58-year-old male with bladder cancer complicated acute myocardial infarction (aMI) were treated by 5-FU 300 mg/day orally for approximately one and a half months as single drug chemotherapy preoperatively." | 1.28 | [Single drug chemotherapy with 5-FU oral administration of bladder cancer]. ( Hasegawa, K; Ikeuchi, T; Kai, Y; Onodera, Y; Sasaki, H; Ueno, M; Yoshikawa, H, 1990) |
"Seventy patients with squamous cell carcinoma or cloacogenic carcinoma of the anus treated from 1979-1987 were reviewed." | 1.28 | Radiotherapy for anal cancer: experience from 1979-1987. ( Ajani, JA; Delclos, L; Hughes, LL; Martin, RG; Rich, TA, 1989) |
" It should be emphasized that these patients had refused any other modality, including surgery, radiation therapy, and standard dosage chemotherapy." | 1.27 | The treatment of primary operable transitional cell cancer of the bladder without cystectomy. Preliminary report. ( Cole, DR; Pung, F; Pung, JL; Sanchez, RS, 1983) |
" During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed." | 1.27 | [Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987) |
"A case of untreated bladder cancer with an unusual clinical course in a 48-year-old man is reported." | 1.27 | [An autopsy case of untreated bladder cancer]. ( Arai, Y; Ishida, A; Pak, K; Tomoyoshi, T, 1987) |
" If toxicity is intolerable, the dosage of CDDP and ADM was decreased in thirty percent." | 1.27 | [Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer]. ( Nakagawa, T; Nishimura, K; Ogawa, O; Taniguchi, T; Yoshimura, N, 1986) |
"The in vivo chemosensitivity test for bladder cancer, using the human bladder cancer xenografts (BT-8 and BT-11 strains) in nude mice (BALB/c) and the BBN-BT-1 bladder cancer strain in BALB/c hetero-mouse which was induced by peroral long-period administration of N-butyl-N-(4-hydroxybutyl) nitrosamine and transplantable into the subcutaneous of mouse, were examined especially in respect to the difference of chemosensitivity between young and old straining and the prospective propriety for clinical application." | 1.27 | [Chemosensitivity test for bladder cancer in a nude-mice experimental system]. ( Kawai, T; Okada, K; Yamauchi, T; Yoshida, O, 1986) |
"Eight patients with deeply invasive bladder cancer were treated with cis-DDP alone or in combination with other drugs following radical cystectomy." | 1.27 | [Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy]. ( Hirano, A; Ogawa, T; Ohkawa, T; Shinka, T; Uekado, Y; Watanabe, T; Yamamoto, S; Yoshida, T, 1985) |
"Thermotherapy combined with tegafur (FT-207) and Picibanil was performed in 13 patients with cancer of the urinary bladder." | 1.27 | [Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma]. ( Arai, T; Honda, M; Kanbe, K; Kaneko, K; Maeda, S; Mukae, K; Murahashi, I; Sakuma, H; Tabata, Y; Takasaki, E, 1985) |
"Squamous cell carcinoma was found in 4 horses and appears to be the most common bladder tumor in the horse." | 1.27 | Neoplasia of the equine urinary bladder as a cause of hematuria. ( Carlson, GP; Fischer, AT; Hackett, RP; Spier, S, 1985) |
"Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months." | 1.26 | Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981) |
"Thiotepa was found to produce marked acantholysis in 43 per cent of those studied." | 1.26 | The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture. ( Adelstein, E; Haigh, J; Khare, N; Oxenhandler, R; Ross, G; Weaver, D, 1980) |
"Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract." | 1.26 | Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982) |
"Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors." | 1.26 | Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. ( Soloway, MS, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 81 (49.09) | 18.7374 |
1990's | 40 (24.24) | 18.2507 |
2000's | 27 (16.36) | 29.6817 |
2010's | 17 (10.30) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Liaw, CC | 2 |
Chuang, CK | 2 |
Chang, YH | 1 |
Liao, TY | 1 |
Chang, JW | 1 |
Juan, YH | 1 |
Tselis, N | 1 |
Prott, FJ | 1 |
Ott, O | 1 |
Weiss, C | 1 |
Rödel, C | 2 |
Zilli, T | 1 |
Betz, M | 1 |
Bieri, S | 1 |
Ris, F | 1 |
Roche, B | 1 |
Roth, AD | 1 |
Allal, AS | 1 |
Mitin, T | 2 |
Hunt, D | 1 |
Shipley, WU | 3 |
Kaufman, DS | 3 |
Uzzo, R | 1 |
Wu, CL | 1 |
Buyyounouski, MK | 1 |
Sandler, H | 1 |
Zietman, AL | 3 |
Huddart, RA | 2 |
Hall, E | 1 |
Hussain, SA | 3 |
Jenkins, P | 1 |
Rawlings, C | 1 |
Tremlett, J | 1 |
Crundwell, M | 1 |
Adab, FA | 1 |
Sheehan, D | 1 |
Syndikus, I | 1 |
Hendron, C | 1 |
Lewis, R | 1 |
Waters, R | 1 |
James, ND | 3 |
Gunderson, LL | 1 |
Moughan, J | 1 |
Ajani, JA | 3 |
Pedersen, JE | 1 |
Winter, KA | 1 |
Benson, AB | 1 |
Thomas, CR | 1 |
Mayer, RJ | 1 |
Haddock, MG | 2 |
Rich, TA | 3 |
Willett, CG | 2 |
Miyata, Y | 1 |
Nomata, K | 1 |
Ohba, K | 1 |
Matsuo, T | 1 |
Hayashi, N | 2 |
Sakamoto, I | 1 |
Uetani, M | 1 |
Sakai, H | 1 |
Gakis, G | 1 |
Morgan, TM | 1 |
Daneshmand, S | 1 |
Keegan, KA | 1 |
Todenhöfer, T | 1 |
Mischinger, J | 1 |
Schubert, T | 1 |
Zaid, HB | 1 |
Hrbacek, J | 1 |
Ali-El-Dein, B | 1 |
Clayman, RH | 1 |
Galland, S | 1 |
Olugbade, K | 1 |
Rink, M | 1 |
Fritsche, HM | 1 |
Burger, M | 1 |
Chang, SS | 1 |
Babjuk, M | 1 |
Thalmann, GN | 1 |
Stenzl, A | 1 |
Efstathiou, JA | 1 |
Li, L | 1 |
Zhang, CL | 1 |
Kang, L | 1 |
Wang, RF | 1 |
Yan, P | 1 |
Zhao, Q | 1 |
Yin, L | 1 |
Guo, FQ | 1 |
George, A | 1 |
Heney, NM | 2 |
Uzzo, RG | 1 |
Dreicer, R | 1 |
Wallace, HJ | 1 |
Souhami, L | 2 |
Dobelbower, MC | 1 |
Sandler, HM | 1 |
Poortmans, PM | 1 |
Richaud, P | 1 |
Collette, L | 2 |
Ho Goey, S | 1 |
Pierart, M | 1 |
Van Der Hulst, M | 1 |
Bolla, M | 1 |
Highley, MS | 1 |
Griffiths, GO | 1 |
Uscinska, BM | 1 |
Barber, JB | 1 |
Parmar, MK | 1 |
Harper, PG | 1 |
Nishikawa, T | 1 |
Kohjimoto, Y | 1 |
Nishihata, M | 1 |
Ebisuno, S | 1 |
Hara, I | 1 |
Seo, YR | 1 |
Kim, SH | 1 |
Kim, HJ | 1 |
Kim, CK | 1 |
Park, SK | 1 |
Koh, ES | 1 |
Hong, DS | 1 |
Lagrange, JL | 1 |
Bascoul-Mollevi, C | 1 |
Geoffrois, L | 1 |
Beckendorf, V | 1 |
Ferrero, JM | 1 |
Joly, F | 1 |
Allouache, N | 1 |
Bachaud, JM | 1 |
Chevreau, C | 1 |
Kramar, A | 1 |
Chauvet, B | 2 |
Bhattacharyya, M | 1 |
Powles, T | 1 |
Mutsvangwa, K | 1 |
Wilson, P | 1 |
Oliver, T | 1 |
Shamash, J | 1 |
De Bari, B | 1 |
Lestrade, L | 1 |
Chekrine, T | 1 |
Shakir Shakir, I | 1 |
Ardiet, JM | 1 |
Chapet, O | 1 |
Mornex, F | 1 |
Simpson, GR | 1 |
Horvath, A | 1 |
Annels, NE | 1 |
Pencavel, T | 1 |
Metcalf, S | 1 |
Seth, R | 1 |
Peschard, P | 1 |
Price, T | 1 |
Coffin, RS | 1 |
Mostafid, H | 1 |
Melcher, AA | 1 |
Harrington, KJ | 1 |
Pandha, HS | 1 |
Mistrangelo, M | 1 |
Pelosi, E | 1 |
Bellò, M | 1 |
Ricardi, U | 1 |
Milanesi, E | 1 |
Cassoni, P | 1 |
Baccega, M | 1 |
Filippini, C | 1 |
Racca, P | 1 |
Lesca, A | 1 |
Munoz, FH | 1 |
Fora, G | 1 |
Skanjeti, A | 1 |
Cravero, F | 1 |
Morino, M | 1 |
Kachnic, LA | 1 |
Winter, K | 1 |
Myerson, RJ | 1 |
Goodyear, MD | 1 |
Willins, J | 1 |
Esthappan, J | 1 |
Rotman, M | 3 |
Parikh, PJ | 1 |
Safran, H | 1 |
Maezawa, T | 1 |
Yonese, J | 2 |
Tsukamoto, T | 1 |
Ishii, N | 1 |
Fukui, I | 2 |
Hirano, Y | 2 |
Kageyama, S | 1 |
Ushiyama, T | 2 |
Suzuki, K | 3 |
Fujita, K | 1 |
Chen, WC | 1 |
Chen, MF | 1 |
Chen, CS | 1 |
Lin, PY | 1 |
Chang, PL | 1 |
Chu, SH | 1 |
Wu, CT | 1 |
Hong, JH | 1 |
Graf, R | 1 |
Wust, P | 1 |
Hildebrandt, B | 1 |
Gögler, H | 1 |
Ullrich, R | 1 |
Herrmann, R | 1 |
Riess, H | 1 |
Felix, R | 1 |
LYTTON, B | 1 |
MARK, JB | 1 |
HARVARD, BM | 1 |
REITEMEIER, RJ | 1 |
MOERTEL, CG | 1 |
BLACKBURN, CM | 1 |
HARROLD, MW | 1 |
EDWARDS, CN | 1 |
GRAVEY, FK | 1 |
Peyromaure, M | 1 |
Slama, J | 1 |
Beuzeboc, P | 1 |
Ponvert, D | 1 |
Debré, B | 1 |
Zerbib, M | 1 |
Goffin, JR | 1 |
Rajan, R | 1 |
Touboul, E | 2 |
Moureau-Zabotto, L | 1 |
Lerouge, D | 1 |
Pène, F | 2 |
Deniaud-Alexandre, E | 1 |
Tiret, E | 2 |
Sezeur, A | 1 |
Houry, S | 1 |
Gallot, D | 2 |
Parc, R | 2 |
Schlienger, M | 2 |
Laugier, A | 2 |
Stocken, DD | 1 |
Peake, DR | 1 |
Glaholm, JG | 2 |
Zarkar, A | 1 |
Wallace, DM | 2 |
George, L | 1 |
Bladou, F | 1 |
Bardou, VJ | 1 |
Gravis, G | 1 |
Tallet, A | 1 |
Alzieu, C | 1 |
Serment, G | 1 |
Salem, N | 1 |
Furuse, H | 1 |
Harada, M | 1 |
Mugiya, S | 1 |
Ozono, S | 1 |
Di Lorenzo, G | 1 |
Autorino, R | 1 |
Giordano, A | 1 |
Giuliano, M | 1 |
D'Armiento, M | 1 |
Bianco, AR | 1 |
De Placido, S | 1 |
Patel, B | 1 |
Forman, J | 2 |
Fontana, J | 1 |
Frazier, A | 1 |
Pontes, E | 1 |
Vaishampayan, U | 1 |
Woodruff, CA | 1 |
Amrikachi, M | 1 |
Hsu, S | 1 |
Lin, CC | 1 |
Hsu, CH | 1 |
Huang, CY | 1 |
Cheng, AL | 1 |
Vogelzang, NJ | 1 |
Pu, YS | 1 |
Siefker-Radtke, A | 1 |
Sanghera, P | 1 |
Ho, K | 1 |
Muscroft, T | 1 |
Hartley, A | 1 |
Higano, CS | 2 |
Tangen, CM | 1 |
Sakr, WA | 1 |
Faulkner, J | 1 |
Rivkin, SE | 1 |
Meyers, FJ | 1 |
Hussain, M | 1 |
Baker, LH | 1 |
Russell, KJ | 3 |
Crawford, ED | 3 |
Shrivastav, S | 1 |
Paulson, DF | 1 |
Harada, T | 1 |
Ohmura, H | 1 |
Nishizawa, O | 1 |
Tsuchida, S | 1 |
Salem, PA | 1 |
Richards, B | 1 |
Bastable, JR | 1 |
Freedman, L | 1 |
Glashan, RW | 3 |
Harris, G | 1 |
Newling, DW | 1 |
Robinson, MR | 2 |
Smith, PH | 2 |
Torti, FM | 1 |
Harker, WG | 1 |
Akiyama, J | 1 |
Sagara, Y | 1 |
Takeda, Y | 1 |
Mishina, T | 1 |
Kobayashi, T | 1 |
Maegawa, M | 1 |
Nakao, M | 1 |
Nakagawa, S | 1 |
Watanabe, H | 1 |
Tiver, KW | 1 |
Langlands, AO | 1 |
Cummings, B | 1 |
Keane, T | 1 |
Thomas, G | 1 |
Harwood, A | 1 |
Rider, W | 1 |
Carey, RW | 1 |
Kihara, K | 3 |
Kusuyama, H | 2 |
Washizuka, M | 3 |
Kawai, T | 4 |
Fujioka, H | 2 |
Tada, Y | 1 |
Nakano, E | 1 |
Matsuda, M | 1 |
Osafune, M | 2 |
Sagawa, S | 1 |
Takaha, M | 1 |
Sonoda, T | 1 |
Tashiro, K | 2 |
Machida, T | 3 |
Masuda, F | 1 |
Ohishi, Y | 1 |
Cole, DR | 1 |
Pung, JL | 1 |
Sanchez, RS | 1 |
Pung, F | 1 |
Sulkes, A | 1 |
Fuks, Z | 1 |
Kotake, T | 3 |
Usami, M | 1 |
Miki, T | 2 |
Kuroda, M | 1 |
Obata, K | 3 |
Takasugi, Y | 1 |
Leissner, KH | 1 |
Gustavsson, B | 1 |
Weaver, D | 1 |
Khare, N | 1 |
Haigh, J | 1 |
Adelstein, E | 1 |
Oxenhandler, R | 1 |
Ross, G | 1 |
Konnak, JW | 1 |
Wallace, S | 1 |
Chuang, VP | 1 |
Samuels, M | 1 |
Johnson, D | 1 |
Sakuramoto, T | 1 |
Ogawa, M | 2 |
Trindade, A | 1 |
Samuels, ML | 1 |
Logothetis, CJ | 1 |
McGeorge, A | 1 |
Hart, AJ | 1 |
Rundle, JS | 1 |
McVie, JG | 1 |
Calman, KC | 1 |
Veronesi, A | 5 |
Magri, MD | 2 |
Figoli, F | 1 |
Tirelli, U | 1 |
Galligioni, E | 2 |
Trovò, MG | 2 |
Merlo, A | 3 |
Dal Bò, V | 5 |
Tumolo, S | 1 |
Grigoletto, E | 1 |
Smalley, RV | 1 |
Bartolucci, AA | 1 |
Hemstreet, G | 1 |
Hester, M | 1 |
Zimm, S | 1 |
Wampler, GL | 1 |
Martino, S | 1 |
Samal, B | 1 |
Al-Sarraf, M | 3 |
Kattan, J | 1 |
Culine, S | 1 |
Theodore, C | 2 |
Droz, JP | 1 |
Kulaylat, MN | 1 |
Doerr, R | 1 |
Butler, B | 1 |
Satchidanand, SK | 1 |
Singh, A | 1 |
Nakagawa, J | 1 |
Nakahara, M | 1 |
Kitajima, N | 1 |
Mizutani, Y | 3 |
Fukumoto, M | 1 |
Bonavida, B | 2 |
Yoshida, O | 5 |
Lo Re, G | 3 |
Carbone, A | 3 |
Talamini, R | 2 |
Santarossa, S | 1 |
Francini, M | 4 |
Monfardini, S | 3 |
Ohashi, Y | 1 |
Akaza, H | 2 |
Isaka, S | 2 |
Kagawa, S | 1 |
Koiso, K | 2 |
Matsumura, Y | 2 |
Niijima, T | 2 |
Smith, DE | 2 |
Shah, KH | 1 |
Rao, AR | 1 |
Frost, DB | 1 |
Latino, F | 1 |
Anderson, PJ | 1 |
Peddada, AV | 1 |
Kagan, AR | 1 |
Buffat, L | 1 |
Lefkopoulos, D | 1 |
Malafosse, M | 1 |
Morrison, WH | 1 |
Ota, D | 1 |
Levin, B | 1 |
Housset, M | 3 |
Maulard, C | 1 |
Chretien, Y | 3 |
Dufour, B | 3 |
Delanian, S | 1 |
Huart, J | 1 |
Colardelle, F | 1 |
Brunel, P | 1 |
Baillet, F | 2 |
Kapp, KS | 1 |
Kapp, DS | 1 |
Stuecklschweiger, G | 1 |
Berger, A | 1 |
Geyer, E | 1 |
Naito, S | 2 |
Hasegawa, S | 1 |
Yokomizo, A | 1 |
Koga, H | 1 |
Kotoh, S | 1 |
Kuwano, M | 1 |
Kumazawa, J | 3 |
Mejean, A | 2 |
Durdux, C | 2 |
Kondás, J | 1 |
Engloner, L | 1 |
Váczi, L | 1 |
Kondér, G | 1 |
Fraunholz, IB | 1 |
Adamietz, IA | 1 |
Lorenz, M | 1 |
Staib-Sebler, E | 1 |
Böttcher, HD | 1 |
McCaffrey, JA | 1 |
Hilton, S | 1 |
Mazumdar, M | 1 |
Sadan, S | 1 |
Heineman, M | 1 |
Hirsch, J | 1 |
Kelly, WK | 1 |
Scher, HI | 1 |
Bajorin, DF | 1 |
Iguchi, A | 2 |
Sagiyama, K | 2 |
Ariyoshi, A | 2 |
Osada, Y | 2 |
Omoto, T | 2 |
Kuriya, N | 1 |
Kish, JA | 1 |
Wolf, MK | 1 |
Schellhammer, PF | 1 |
Hussain, MH | 2 |
Einstein, AB | 1 |
Otto, T | 1 |
Krege, S | 1 |
Otto, B | 1 |
Goepel, M | 1 |
Rübben, H | 1 |
Danesi, DT | 1 |
Arcangeli, G | 1 |
Cruciani, E | 1 |
Mecozzi, A | 1 |
Saracino, B | 1 |
Giacobini, S | 1 |
Pannunzio, E | 1 |
Biggio, A | 1 |
Orefici, F | 1 |
Tsujinaka, T | 1 |
Murotani, M | 1 |
Iihara, K | 1 |
Takami, M | 1 |
Takada, T | 1 |
Kitada, M | 1 |
Tsukahara, Y | 1 |
Shibata, T | 1 |
Niinobu, T | 1 |
Inoue, T | 1 |
Kimura, M | 2 |
Hanada, M | 1 |
Nose, T | 1 |
Birkenhake, S | 1 |
Martus, P | 1 |
Kühn, R | 2 |
Schrott, KM | 2 |
Sauer, R | 3 |
Takahashi, Y | 1 |
Yamamoto, N | 1 |
Deguchi, T | 1 |
Kuriyama, M | 1 |
Yoh, M | 1 |
Yasuda, M | 1 |
Nakano, M | 1 |
Kawada, Y | 1 |
Takeuchi, T | 1 |
Shinoda, I | 1 |
Félix-Faure, C | 1 |
Davin, JL | 1 |
Berger, C | 1 |
Vincent, P | 1 |
Reboul, F | 1 |
Schmitt, T | 1 |
Armand, C | 1 |
Mille, D | 1 |
Favrel-Tchakamian, V | 1 |
Gilloz, A | 1 |
Zehr, EM | 1 |
Althausen, AF | 1 |
McGovern, FJ | 1 |
Kitsukawa, S | 1 |
Kinn, T | 1 |
Yoshida, T | 2 |
Izutami, T | 1 |
Ishikawa, Y | 1 |
Teicher, BA | 1 |
Ara, G | 1 |
Buxton, D | 1 |
Leonard, J | 1 |
Schaub, RG | 1 |
Oh, WK | 1 |
Manola, J | 1 |
Richie, JP | 1 |
Loughlin, KR | 1 |
Kantoff, PW | 1 |
Glass, TR | 1 |
Sakr, W | 1 |
Smith, DC | 1 |
Jones, J | 1 |
Balcerzak, SP | 1 |
Grossman, HB | 1 |
De Mulder, PH | 1 |
Sella, A | 1 |
Koriakine, O | 1 |
Sternberg, CN | 1 |
de Balincourt, C | 1 |
Wada, H | 1 |
Fukushima, M | 2 |
Ukimura, O | 1 |
Kawauchi, A | 1 |
Moffitt, DD | 1 |
Peake, D | 1 |
Griffiths, JR | 1 |
McIntyre, DJ | 1 |
Howe, FA | 1 |
McSheehy, PM | 1 |
Rodrigues, LM | 1 |
Wadsworth, P | 1 |
Price, NM | 1 |
Lofts, F | 1 |
Nicholson, G | 1 |
Smid, K | 1 |
Noordhuis, P | 1 |
Peters, GJ | 1 |
Stubbs, M | 1 |
Iizumi, T | 1 |
Hariu, K | 1 |
Sato, M | 1 |
Sato, S | 2 |
Shimizu, H | 1 |
Tomomasa, H | 1 |
Umeda, T | 1 |
Grabenbauer, GG | 1 |
Dunst, J | 2 |
Papadopoulos, T | 1 |
Soloway, MS | 5 |
Lundbeck, F | 1 |
Christophersen, IS | 1 |
Houghton, AL | 1 |
Fichardt, T | 1 |
Sandison, AG | 1 |
Morita, M | 1 |
Sato, Y | 1 |
Miyakawa, K | 1 |
Nevin, JE | 2 |
Hoffman, AA | 1 |
Collier, D | 1 |
Cross, RJ | 1 |
Humphrey, CS | 1 |
Robinson, RG | 1 |
Williams, RE | 1 |
Kolosseus, RC | 1 |
Fraley, EE | 1 |
Blackard, CE | 1 |
Melnick, I | 1 |
Baggerly, JT | 1 |
Landes, R | 1 |
Easley, CA | 1 |
Sahashi, M | 1 |
Ono, Y | 2 |
Matsuura, O | 1 |
Ohshima, S | 2 |
Wada, S | 1 |
Yasumoto, R | 1 |
Kashihara, N | 1 |
Kishimoto, T | 1 |
Maekawa, M | 1 |
Hayahara, N | 1 |
Kawakita, J | 1 |
Nishijima, T | 1 |
Morikawa, Y | 1 |
Horii, A | 1 |
Doci, R | 1 |
Zucali, R | 1 |
Bombelli, L | 1 |
Montalto, F | 1 |
Lamonica, G | 1 |
Nishiyama, T | 1 |
Sasagawa, T | 1 |
Tanikawa, T | 1 |
Katayama, Y | 1 |
Kawakami, Y | 1 |
Tomita, Y | 1 |
Terunuma, M | 1 |
Osawa, T | 1 |
Kanimoto, Y | 1 |
Suzuki, Y | 1 |
Miwa, Y | 1 |
Akino, H | 1 |
Isomatu, Y | 1 |
Okada, K | 4 |
Bonaventura, A | 1 |
Stewart, JF | 1 |
Boileau, MA | 2 |
Higano, C | 1 |
Collins, C | 2 |
Russell, AH | 1 |
Koh, W | 1 |
Cole, SB | 1 |
Chapman, WH | 2 |
Griffin, TW | 2 |
Ueno, M | 1 |
Yoshikawa, H | 1 |
Hasegawa, K | 1 |
Sasaki, H | 1 |
Onodera, Y | 1 |
Ikeuchi, T | 1 |
Kai, Y | 1 |
Aziz, H | 2 |
Porrazzo, M | 1 |
Choi, KN | 1 |
Silverstein, M | 2 |
Rosenthal, J | 2 |
Laungani, G | 1 |
Macchia, R | 2 |
Yamauchi, T | 2 |
Hida, S | 1 |
Ooishi, K | 1 |
Fujita, T | 1 |
Aso, Y | 1 |
Al-Kourainy, K | 1 |
Crissman, J | 1 |
Ensley, J | 1 |
Kish, J | 1 |
Kelly, J | 1 |
Kubota, Y | 2 |
Kakizaki, H | 1 |
Numasawa, K | 1 |
Kato, H | 1 |
Hughes, LL | 1 |
Delclos, L | 1 |
Martin, RG | 1 |
Nagamoto, A | 1 |
Shuin, T | 1 |
Kondo, I | 1 |
Moriyama, M | 1 |
Satomi, Y | 1 |
Fukushima, S | 1 |
Fukuoka, H | 1 |
Ishizuka, E | 1 |
Furuhata, A | 1 |
Sischy, B | 1 |
Doggett, RL | 1 |
Krall, JM | 1 |
Taylor, DG | 1 |
Sause, WT | 1 |
Lipsett, JA | 1 |
Seydel, HG | 2 |
Morassut, S | 1 |
Carmignani, G | 1 |
Lelli, G | 1 |
Tononi, A | 1 |
Bacchetti, P | 1 |
Maver, P | 1 |
Corrado, G | 1 |
Garofalo, F | 1 |
De Santis, P | 1 |
Pannuti, F | 1 |
Muff, NS | 1 |
Shetabi, H | 1 |
Danil'chenko, SA | 1 |
Shlopov, VG | 1 |
Serniak, PS | 1 |
Geev, IuV | 1 |
John, MJ | 1 |
Flam, M | 1 |
Lovalvo, L | 1 |
Mowry, PA | 1 |
Reichard, U | 1 |
Wolf, N | 1 |
Uekado, Y | 2 |
Shinka, T | 2 |
Hirano, A | 2 |
Ohkawa, T | 2 |
Sato, K | 1 |
Hatano, T | 1 |
Miyazato, T | 1 |
Saito, S | 1 |
Kashiwabara, N | 1 |
Igarashi, M | 1 |
Koyama, Y | 1 |
Hayakawa, M | 1 |
Osawa, A | 1 |
Amiel, J | 1 |
Quintens, H | 1 |
Thyss, A | 1 |
Caldani, C | 1 |
Schneider, M | 1 |
Toubol, J | 1 |
Maru, A | 1 |
Nakagami, Y | 1 |
Peppe, H | 1 |
Bianchi, C | 1 |
Bianchi, O | 1 |
Stringa, S | 1 |
Ireton, RC | 1 |
Koh, WJ | 1 |
Griffin, BR | 1 |
Pak, K | 1 |
Ishida, A | 1 |
Arai, Y | 1 |
Tomoyoshi, T | 1 |
Sorio, R | 1 |
Saracchini, S | 1 |
Takahashi, T | 1 |
Sakata, Y | 1 |
Tai, K | 1 |
Nagayama, T | 1 |
Ishii, Y | 1 |
Ueda, T | 1 |
Kondo, N | 1 |
Ikemoto, I | 1 |
Ogawa, O | 1 |
Yoshimura, N | 1 |
Taniguchi, T | 1 |
Nishimura, K | 1 |
Nakagawa, T | 1 |
Choi, K | 1 |
Braverman, A | 1 |
Laungani, GB | 1 |
Hrushesky, WJ | 1 |
Roemeling, RV | 1 |
Wood, PA | 1 |
Langevin, TR | 1 |
Lange, P | 1 |
Farley, E | 1 |
Ogawa, T | 1 |
Yamamoto, S | 1 |
Watanabe, T | 1 |
Leichman, L | 1 |
Nigro, N | 1 |
Vaitkevicius, VK | 1 |
Considine, B | 1 |
Buroker, T | 1 |
Bradley, G | 1 |
Olchowski, S | 1 |
Cummings, G | 1 |
Leichman, C | 1 |
Murahashi, I | 1 |
Mukae, K | 1 |
Tabata, Y | 1 |
Sakuma, H | 1 |
Kanbe, K | 1 |
Arai, T | 1 |
Kaneko, K | 1 |
Honda, M | 1 |
Maeda, S | 1 |
Takasaki, E | 1 |
Fischer, AT | 1 |
Spier, S | 1 |
Carlson, GP | 1 |
Hackett, RP | 1 |
Nakada, T | 1 |
Akiya, T | 1 |
Yoshikawa, M | 1 |
Umeda, K | 1 |
Katayama, T | 1 |
Tomiyama, T | 1 |
Greene, LF | 1 |
Mulcahy, JJ | 1 |
Warren, MM | 1 |
Dockerty, MB | 1 |
deKernion, JB | 1 |
Rose, D | 1 |
Persky, L | 1 |
Witek, JT | 1 |
Spencer, RP | 1 |
Harrison, LH | 1 |
Cox, CE | 1 |
Banks, KW | 1 |
Boyce, WH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabi[NCT00055601] | Phase 2 | 97 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
A Phase II Feasibility Study of Combined Accelerated External Radiation and Chemotherapy With 5FU and CDDP Following Transurethral Resection in Patients With Muscle Invasive Transitional Carcinoma of the Bladder - T2-T3, N0, M0 (UICC 1992)[NCT00003642] | Phase 2 | 43 participants (Anticipated) | Interventional | 1998-10-31 | Terminated (stopped due to low accrual) | ||
A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract[NCT00003175] | Phase 2 | 45 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer[NCT01495676] | 69 participants (Actual) | Interventional | 2011-07-06 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Bladder-intact survival was measured from the date of randomization to occurrence of cystectomy or death. Five-year rates were estimated using the Kaplan-Meier method. (NCT00055601)
Timeframe: From the date of randomization to five years.
Intervention | percentage of participants (Number) |
---|---|
Pelvic RT + Paclitaxel + Cisplatin | 67 |
Pelvic RT + Fluorouracil + Cisplatin | 71 |
Complete response requires the absence of any tumor in the tumor-site biopsy specimen or elsewhere and a bimanual exam that does not indicate the presence of a tumor mass. (NCT00055601)
Timeframe: From randomization to eight weeks
Intervention | percentage of participants (Number) |
---|---|
Pelvic RT + Paclitaxel + Cisplatin | 72 |
Pelvic RT + Fluorouracil + Cisplatin | 62 |
Radiation therapy and chemotherapy per protocol or within acceptable variation guidelines based on central review. The study was designed for a two-sided binomial test with 87% power and a significance level of 0.05 with a null hypothesis of a 70% completion rate against the alternative 90% completion rate. For each arm, more than 34 out of 43 evaluable patients completing the treatment, would indicate to reject the null hypothesis for a better treatment completion rate. Fewer than 24 out 43 evaluable patients completing the treatment would indicate to reject the null hypothesis for a worse treatment completion rate. Otherwise, the conclusion would be that there is not enough evidence to reject the null hypothesis of a 70% completion rate in either direction. (NCT00055601)
Timeframe: From randomization to 11 weeks
Intervention | percentage of participants (Number) |
---|---|
Pelvic RT + Paclitaxel + Cisplatin | 67 |
Pelvic RT + Fluorouracil + Cisplatin | 53 |
14 reviews available for fluorouracil and Carcinoma, Transitional Cell
Article | Year |
---|---|
[Radiochemotherapy for invasive bladder cancer : An update].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio | 2018 |
[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2012 |
Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carbopl | 2004 |
Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2004 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cispla | 2006 |
Systemic therapy of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transit | 1984 |
Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1983 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti | 1995 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
[Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin | 1998 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
Invasive bladder cancer: organ preservation by radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2002 |
Intravesical and systemic chemotherapy of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphami | 1977 |
33 trials available for fluorouracil and Carcinoma, Transitional Cell
Article | Year |
---|---|
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Ad | 2008 |
A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Infusion Pu | 2009 |
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 2011 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional | 2013 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Fema | 1983 |
The treatment of advanced carcinoma of the bladder with combination chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cyclophosphamide; Dox | 1982 |
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T | 1981 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherap | 1994 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1997 |
Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Ant | 1997 |
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, | 1997 |
Combined treatment of invasive bladder carcinoma with transurethral resection, induction chemotherapy, and radical radiotherapy plus concomitant protracted infusion of cisplatin and 5-fluorouracil: a phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Dose- | 1997 |
A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1998 |
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1999 |
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 2001 |
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combi | 2000 |
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2001 |
Combination chemotherapy for advanced urothelial-tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1992 |
Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell | 1987 |
[Phase II study of 5-FU tablet in bladder tumor].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Carcinoma, Transitional Cell; Drug E | 1989 |
Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladd
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1987 |
Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.
Topics: Administration, Intravesical; Administration, Oral; Aged; Carcinoma, Transitional Cell; Combined Mod | 1987 |
119 other studies available for fluorouracil and Carcinoma, Transitional Cell
Article | Year |
---|---|
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2017 |
Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2013 |
Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cyto | 2015 |
Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cells, Cul | 2009 |
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; F | 2010 |
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cr | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
[Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 | 2002 |
Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
Topics: Carcinoma, Transitional Cell; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Oxidoreducta | 2003 |
Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 2003 |
Continuous intraarterial chemotherapy in advanced bladder cancer. A preliminary report.
Topics: Carcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Fluorouracil; Humans; Neoplasms; Urin | 1963 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
TREATMENT OF BLADDER TUMORS BY DIRECT INSTILLATION OF 5-FLUOROURACIL. EXPERIMENTAL OBSERVATIONS IN DOGS.
Topics: Amines; Animals; Carcinogens; Carcinoma; Carcinoma, Transitional Cell; Dogs; Fluorouracil; Gastroent | 1964 |
Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch | 2003 |
[Orotate phosphoribosyl transferase in bladder cancer].
Topics: Carcinoma, Transitional Cell; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Neoplasm Stagi | 2004 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma in Situ; Carcinoma | 2005 |
Zosteriform metastatic transitional cell carcinoma.
Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional | 2005 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans | 2007 |
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
In vitro chemotherapy testing of transitional cell carcinoma.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Cells, Cultured; Cisplatin; Cyclopho | 1980 |
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female; | 1982 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
[Clinical application of tegafur suppositories for bladder tumor].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Mid | 1983 |
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Car | 1984 |
Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum/5-fluorouracil treatment.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transit | 1984 |
[Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1984 |
[Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1984 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
The treatment of primary operable transitional cell cancer of the bladder without cystectomy. Preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Doxorubicin; Fem | 1983 |
Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Doxor | 1983 |
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce | 1983 |
Intravesical high dose 5-fluorouracil instillations combined with allopurinol--a therapeutic alternative in the treatment of multiple bladder tumors.
Topics: Allopurinol; Carcinoma, Transitional Cell; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm | 1984 |
The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleolus; Fluorouracil; Humans; In Vitro | 1980 |
Conservative management of low grade neoplasms of the male urethra: a preliminary report.
Topics: Adult; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Middle Ag | 1980 |
Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Thera | 1982 |
[Chemotherapy of metastatic urothelial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Therapy, Combinatio | 1982 |
Chemotherapy of carcinoma of renal pelvis: preliminary report.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1981 |
Combination chemotherapy with adriamycin and 5-fluorouracil in advanced bladder carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1982 |
Response of metastatic cloacogenic carcinoma to treatment with semustine.
Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu | 1981 |
Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1980 |
[A case of advanced cancer of the renal pelvis effectively treated by continuous infusion of 5-fluorouracil].
Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusio | 1994 |
Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Northern; Carcinoma, Transitional Cell; Cisplatin; D | 1994 |
Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra | 1994 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1994 |
Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.
Topics: Anal Gland Neoplasms; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Co | 1993 |
Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1993 |
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 1995 |
[Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy?].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1996 |
Transurethral resection and intra-arterial chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1996 |
[Outcome of simultaneous radiochemotherapy of anal carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1997 |
[Preoperative chemoradiation therapy for advanced rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1997 |
Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplasti | 1998 |
Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic | 1998 |
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1998 |
[Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1998 |
[Concurrent chemotherapy and hyperfractionated radiotherapy for non-operable carcinoma of the bladder].
Topics: Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiat | 1998 |
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Moda | 1997 |
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Trans | 2001 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb | 2001 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Dihydrouracil Dehydrogenase (NADP); Enzym | 2002 |
Phase II study of adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder.
Topics: Bone Marrow; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1979 |
A toxicity study of the treatment of T3 bladder tumours with a combination of radiotherapy and chemotherapy.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A | 1977 |
Management of urinary bladder cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fem | 1978 |
Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorub | 1978 |
Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the maxillary sinus.
Topics: Bromodeoxyuridine; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; | 1978 |
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc | 1975 |
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; | 1976 |
Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.
Topics: Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combination; Evaluation Studies as To | 1976 |
Bladder cancer in man. An update.
Topics: Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Prognosis; RNA Viruses; Urinary Bladder Ne | 1975 |
Single and combination chemotherapy for primary murine bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Dactinomycin; Disease Models, An | 1975 |
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou | 1975 |
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1992 |
Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
[Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
[Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; | 1990 |
[Single drug chemotherapy with 5-FU oral administration of bladder cancer].
Topics: Administration, Oral; Carcinoma, Transitional Cell; Fluorodeoxyuridylate; Fluorouracil; Humans; Male | 1990 |
Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Fluorourac | 1990 |
[Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1985 |
Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1988 |
Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1989 |
Radiotherapy for anal cancer: experience from 1979-1987.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 1989 |
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cobalt Radioisot | 1989 |
Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: a feasible and possibly effective approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1989 |
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide | 1989 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Cancer, | 1986 |
Feasibility of non-surgical definitive management of anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1987 |
Adjuvant chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl | 1987 |
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr | 1988 |
[Combination transurethral resection and systematic chemotherapy as primary treatment of infiltrating bladder tumors (pT2-pT4 NxM0)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1988 |
[Cutaneous metastasis of a cloacogenic tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transitional Cell; | 1987 |
Pre surgery chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Mo | 1988 |
Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Flu | 1988 |
[An autopsy case of untreated bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin | 1987 |
Combination chemotherapy with fluorouracil, adriamycin, cis-platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1986 |
[Combined therapy with 5-fluorouracil, doxorubicin, cis-diamminedichloroplatinum on advanced urothelial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1987 |
[A case of complete remission of distant metastases of a renal pelvic tumor by combination chemotherapy with mitomycin, cyclophosphamide and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide; Fema | 1986 |
[Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional Cell; | 1986 |
Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1987 |
High-dose intensity systemic therapy of metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Circadian Rhythm | 1987 |
[Chemosensitivity test for bladder cancer in a nude-mice experimental system].
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-For | 1986 |
[Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1985 |
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1985 |
[Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma].
Topics: Adult; Aged; Biological Products; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fl | 1985 |
Neoplasia of the equine urinary bladder as a cause of hematuria.
Topics: Animals; Biopsy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cystoscopy; Female; Fibroma | 1985 |
Therapeutic experience of advanced urothelial tract tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Mo | 1985 |
[Effects of intravesical instillation of antitumor agents on bladder cancer].
Topics: Aged; Carcinoma, Papillary; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Injections; | 1972 |
Primary transitional cell carcinoma of the prostate.
Topics: Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Diethylstilbestrol; F | 1973 |
Effect of chemotherapeutic agents on bladder cancer: a new animal model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamin | 1973 |
Scan evidence of decrease in size of intrahepatic tumors after chemotherapy. A case report.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cecal Neoplasms; Doxorubicin; Female; Fluorouracil; Human | 1974 |
Distant metastases from beta-naphthylamine induced vesical tumors in dogs.
Topics: Animals; Carcinogens; Carcinoma, Transitional Cell; Dogs; Female; Fluorouracil; Lung Neoplasms; Naph | 1969 |